Correction: Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS (PLoS ONE (2017) 12:7 (e0181863) DOI: 10.1371/journal.pone.0181863);Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  Brun, Paola ^a   Scarpa, Melania ^a   Marchiori, Chiara ^a   Sarasin, Gloria ^a   Caputi, Valentina ^a   Porzionato, Andrea ^a   Giron, Maria Cecilia ^a   Palù, Giorgio ^a   Castagliuolo, Ignazio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; NEURONAL NITRIC OXIDE SYNTHASE; PERIPHERIN; PROTEIN S100B; SUBSTANCE P; TUMOR NECROSIS FACTOR; CYTOKINE; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTERITIS; HERPES SIMPLEX VIRUS 1; INTESTINAL DYSMOTILITY; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; MALE; MOUSE; MUSCLE ISOMETRIC CONTRACTION; MYENTERIC PLEXUS; NONHUMAN; SACCHAROMYCES BOULARDII; SUPPLEMENTATION; ANIMAL; C57BL MOUSE; COLON; DIARRHEA; DISEASE MODEL; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; GROWTH, DEVELOPMENT AND AGING; HERPES SIMPLEX; HUMAN ALPHAHERPESVIRUS 1; ILEUM; INFLAMMATION; IRRITABLE BOWEL SYNDROME; METABOLISM; MICROBIOLOGY; MUSCLE; PATHOGENICITY; VIROLOGY;

ANIMALS; COLON; CYTOKINES; DIARRHEA; DISEASE MODELS, ANIMAL; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL MOTILITY; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; ILEUM; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-4; IRRITABLE BOWEL SYNDROME; MALE; MICE; MICE, INBRED C57BL; MUSCLES; MYENTERIC PLEXUS; PROBIOTICS; SACCHAROMYCES BOULARDII; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85025679320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0188563     Document Type: Erratum

References (56)

1. Spiegel BM (2009) The burden of IBS: looking at metrics. Curr Gastroenterol Rep 11: 265–269. PMID: 19615301
2. Chey WD, Kurlander J, Eswaran S (2015) Irritable bowel syndrome: a clinical review. JAMA 313: 949–958. https://doi.org/10.1001/jama.2015.0954 PMID: 25734736
3. Canavan C, West J, Card T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6: 71–80. https://doi.org/10.2147/CLEP.S40245 PMID: 24523597
4. Demir IE, Schafer KH, Tieftrunk E, Friess H, Ceyhan GO (2013) Neural plasticity in the gastrointestinal tract: chronic inflammation, neurotrophic signals, and hypersensitivity. Acta Neuropathol 125: 491–509. https://doi.org/10.1007/s00401-013-1099-4 PMID: 23417735
5. Di Nardo G, Blandizzi C, Volta U, Colucci R, Stanghellini V, Barbara G, et al. (2008) Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 28: 25–42. https://doi.org/10.1111/j.1365-2036.2008.03707.x PMID: 18410560
6. De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F (2004) Inflammatory neuropathies of the enteric nervous system. Gastroenterology 126: 1872–1883. PMID: 15188182
7. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126: 693–702. PMID: 14988823
8. Zhang L, Song J, Hou X (2016) Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil 22: 181–192. https://doi.org/10.5056/jnm15137 PMID: 26755686
9. Brun P, Giron MC, Zoppellaro C, Bin A, Porzionato A, De Caro R, et al. (2010) Herpes simplex virus type 1 infection of the rat enteric nervous system evokes small-bowel neuromuscular abnormalities. Gastroenterology 138: 1790–1801. https://doi.org/10.1053/j.gastro.2010.01.036 PMID: 20102717
10. Didari T, Mozaffari S, Nikfar S, Abdollahi M (2015) Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 21: 3072–3084. https://doi.org/10.3748/wjg.v21.i10.3072 PMID: 25780308
11. Gareau MG, Sherman PM, Walker WA (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7: 503–514. https://doi.org/10.1038/nrgastro.2010.117 PMID: 20664519
12. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. (2005) Lactobacillus and bifidobacter-ium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541–551. PMID: 15765388
13. Hemarajata P, Versalovic J (2013) Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol 6: 39–51. https://doi.org/10.1177/ 1756283X12459294 PMID: 23320049
14. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. (2007) Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26: 475–486. https://doi.org/10.1111/j.1365-2036.2007.03362.x PMID: 17635382
15. Kelesidis T, Pothoulakis C (2012) Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol 5: 111–125. https://doi.org/10.1177/1756283X11428502 PMID: 22423260
16. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ (2011) A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 45: 679–683. https://doi.org/10.1097/MCG.0b013e318204593e PMID: 21301358
17. Nagy A, Gertsenstein M, Vintersten K, Behringer R (2006) Quick and Humane Sacrifice of a Mouse by Cervical Dislocation. CSH Protoc 1:2006.
18. Garcia JH, Wagner S, Liu KF, Hu Xj (1995) Early reperfusion as a rationale from of therapy in ischemic stroke. Rev Neurol 23:1067–1073. PMID: 8556595
19. Brun P, Giron MC, Qesari M, Porzionato A, Caputi V, Zoppellaro C, et al (2013) Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology 145: 1323–1333. https://doi.org/10.1053/j.gastro.2013.08.047 PMID: 23994200
20. Raffa RB, Mathiasen JR, Jacoby HI (1987) Colonic bead expulsion time in normal and mu-opioid receptor deficient (CXBK) mice following central (ICV) administration of mu- and delta-opioid agonists. Life Sci 41: 2229–2234. PMID: 2823042
21. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O (2012) alpha-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 47: 258–267. https://doi.org/10.1016/j.nbd.2012.04.009 PMID: 22549133
22. de Vries P, Soret R, Suply E, Heloury Y, Neunlist M (2010) Postnatal development of myenteric neurochemical phenotype and impact on neuromuscular transmission in the rat colon. Am J Physiol Gastrointest Liver Physiol 299: G539–47. https://doi.org/10.1152/ajpgi.00092.2010 PMID: 20522637
23. Mayer EA, Naliboff BD, Chang L, Coutinho SV (2001) Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 280: G519–524. PMID: 11254476
24. Coutinho SV, Plotsky PM, Sablad M, Miller JC, Zhou H, Bayati AI, et al. (2002) Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 282: G307–316. https://doi.org/10.1152/ajpgi.00240.2001 PMID: 11804852
25. Schwetz I, McRoberts JA, Coutinho SV, Bradesi S, Gale G, Fanselow M, et al. (2005) Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats. Am J Physiol Gastrointest Liver Physiol 289: G704–712. https://doi.org/10.1152/ajpgi.00498.2004 PMID: 15994424
26. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. (2002) Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778–1783. PMID: 12055584
27. Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, et al. (2011) Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106: 1290–1298. https://doi.org/10.1038/ajg.2011.86 PMID: 21427712
28. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S (2008) Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57: 923–929. https://doi.org/10.1136/gut.2007.138982 PMID: 18252749
29. Dothel G, Barbaro MR, Boudin H, Vasina V, Cremon C, Gargano L, et al. (2015) Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 148: 1002–1011 e1004. https://doi.org/10.1053/j.gastro.2015.01.042 PMID: 25655556
30. Fujikawa Y, Tominaga K, Tanaka F, Tanigawa T, Watanabe T, Fujiwara Y, et al (2015) Enteric glial cells are associated with stress-induced colonic hyper-contraction in maternally separated rats. Neurogastroenterol Motil 27:1010–23 https://doi.org/10.1111/nmo.12577 PMID: 25960044
31. Wang P, Du C, Chen FX, Li CQ, Yu YB, Han T, et al (2016) BDNF contributes to IBS-like colonic hypersensitivity via activating the enteroglia-nerve unit. Sci Rep 6: 20320. https://doi.org/10.1038/srep20320PMID: 26837784
32. Numazaki M, Tominaga M (2004) Nociception and TRP Channels. Curr Drug Targets CNS Neurol Dis-ord 3: 479–485. PMID: 15578965
33. Keszthelyi D, Troost FJ, Jonkers DM, Helyes Z, Hamer HM, Ludidi S, et al (2013) Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation? Eur J Pain 17:1299–306 https://doi.org/10.1002/j.1532-2149.2013.00309.xPMID: 23529955
34. Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, et al (2014) Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 2014 6: 630–9.
35. McFarland LV (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16:2202–22 https://doi.org/10.3748/wjg.v16.i18.2202 PMID: 20458757
36. Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J (2013) Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol 50:304–9 https://doi.org/10.1590/S0004-28032013000400012 PMID: 24474234
37. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y (2008) Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 135:568–7938 https://doi.org/10.1053/j.gastro.2008.04.017 PMID: 18570896
38. Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, et al (2015) A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 47: 119–24. https://doi.org/10.1016/j.dld.2014.11.007 PMID: 25488056
39. Floch MH (2005) Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastroenterol 39: S243–246. PMID: 15798491
40. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104: 1033–1049 https://doi.org/10.1038/ajg.2009.25 PMID: 19277023
41. Borruel N, Casellas F, Antolin M, Llopis M, Carol M, Espiin E, et al. (2003) Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 98: 865–870. https://doi.org/10.1111/j.1572-0241.2003.07384.x PMID: 12738469
42. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M (2004) Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53: 821–828. https://doi.org/10.1136/gut.2003.026252 PMID: 15138208
43. Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, et al. (2014) Lactobacillus aci-dophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain—a randomised clinical study. Aliment Pharmacol Ther 40: 200–207. https://doi.org/10.1111/apt. 12800 PMID: 24853043
44. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109: 1547–1561; quiz 1546, 1562. https://doi.org/10.1038/ajg.2014.202 PMID: 25070051
45. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, et al. (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101: 1581–1590. https://doi.org/10.1111/j.1572-0241.2006.00734.x PMID: 16863564
46. McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, et al. (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52: 975–980. PMID: 12801954
47. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, et al. (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343: 69–76. https://doi.org/10.1016/j.bbrc.2006.02.080PMID: 16529714
48. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O’Brien M, et al. (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281: 24449–24454. https://doi.org/10.1074/jbc.M605200200 PMID: 16816386
49. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ (2009) The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 54: 255–263. https://doi.org/10.1007/s10620-008-0357-0 PMID: 18612822
50. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al (2006) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131: 1812–1825. https://doi.org/10.1053/j.gastro.2006.10.001 PMID: 17087945
51. Guslandi M (2011) Treatment of irritable bowel syndrome with Saccharomyces Boulardii. J Clin Gatroenterol 45:740–741
52. Miquel S, Martín R, Lashermes A, Gillet M, Meleine M, Gelot A, et al (2016) Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci Rep 6: 19399. https://doi.org/10.1038/srep19399 PMID: 26775847
53. Darbaky Y, Evrard B, Patrier S, Falenta J, Garcin S, Tridon A, et al (2017) Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. J Appl Microbiol 122: 188–200. https://doi.org/10.1111/jam.13320 PMID: 27718511
54. Ashraf R, Shah NP (2014) Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr 54: 938–956. https://doi.org/10.1080/10408398.2011.619671 PMID: 24499072
55. Barc MC, Charrin-Sarnel C, Rochet V, Bourlioux F, Sandré C, Boureau H, et al. (2008) Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe 14: 229–233. https://doi.org/10.1016/j.anaerobe.2008.04.003PMID: 18511310
56. Rajput IR, Hussain A, Li YL, Zhang X, Xu X, Long MY, et al. (2014) Saccharomyces boulardii and Bacillus subtilis B10 modulate TLRs mediated signaling to induce immunity by chicken BMDCs. J Cell Biochem 115: 189–198. https://doi.org/10.1002/jcb.24650 PMID: 24038094